Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Neurofibromatosis 1 2Glioma 2Colorectal Neoplasms 2Vascular Malformations 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Oligodendroglioma 1Neurofibromatoses 1Neurofibroma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1KRAS Mutant Non-Small Cell Lung Cancer 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1Arteriovenous Malformations 1

Interventions

Surveys and Questionnaires 2Imatinib Mesylate 2talimogene laherparepvec 1pirfenidone 1nilotinib 1mirdametinib 1diphenylcyclopropenone 1cabozantinib 1binimetinib 1Sunitinib 1Sirolimus 1Sevoflurane 1Propofol 1Percutaneous Collagen Induction 1Nitrous Oxide 1Lidocaine 1Lasers, Solid-State 1Lasers 1Glycopyrrolate 1Dexmedetomidine 1Blood Specimen Collection 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neurofibromatoses × mirdametinib × Clear all
NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Sutter Health

Phase 2 Recruiting
10 enrolled
CNSDermatologic

Melanoma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡